HPHA Stock Overview
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Heidelberg Pharma AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.95 |
| 52 Week High | €4.03 |
| 52 Week Low | €2.61 |
| Beta | -0.31 |
| 1 Month Change | -2.96% |
| 3 Month Change | -4.53% |
| 1 Year Change | -25.32% |
| 3 Year Change | -53.17% |
| 5 Year Change | -2.32% |
| Change since IPO | -94.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| HPHA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.3% | 1.8% | -1.2% |
| 1Y | -25.3% | -19.8% | 1.8% |
Return vs Industry: HPHA underperformed the German Biotechs industry which returned -19.8% over the past year.
Return vs Market: HPHA underperformed the German Market which returned 1.8% over the past year.
Price Volatility
| HPHA volatility | |
|---|---|
| HPHA Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HPHA has not had significant price volatility in the past 3 months.
Volatility Over Time: HPHA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 98 | Andreas Pahl | heidelberg-pharma.com |
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors.
Heidelberg Pharma AG Fundamentals Summary
| HPHA fundamental statistics | |
|---|---|
| Market cap | €138.88m |
| Earnings (TTM) | -€18.28m |
| Revenue (TTM) | €9.05m |
15.3x
P/S Ratio-7.6x
P/E RatioIs HPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HPHA income statement (TTM) | |
|---|---|
| Revenue | €9.05m |
| Cost of Revenue | €1.83m |
| Gross Profit | €7.22m |
| Other Expenses | €25.50m |
| Earnings | -€18.28m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
Jul 11, 2024
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 79.75% |
| Net Profit Margin | -201.94% |
| Debt/Equity Ratio | 11.2% |
How did HPHA perform over the long term?
See historical performance and comparison